Zealand Pharma Shares Decline Amid Obesity Drug Trial Side Effects

By EC Assets · Published 8 June 2026

Zealand Pharma A/S experienced a 26% decline in its share price. The drop occurred after the company reported that side effects overshadowed trial data for its obesity drug. A significant number of users discontinued the weight-loss drug during trials due to gastrointestinal issues. The company's shares tumbled in Copenhagen. One-fifth of users stopped taking the drug. This discontinuation rate is attributed to gastrointestinal problems. Despite these issues, the Boehringer-Zealand obesity drug has shown promise in reducing visceral and liver fat. This aspect of the drug's performance offers a different perspective on its overall trial results. Separately, a new daily tablet for type 2 diabetes has shown effectiveness in lowering blood sugar and aiding weight loss, comparable to Ozempic. The healthcare sector, among others, is currently experiencing fierce price wars. These conditions stem from what large companies describe as China's overproduction model. 42% of large companies report negative impacts from this model. This article is intended for informational purposes only. It does not constitute investment advice.